spacer
home > ebr > Spring 2002
PUBLICATIONS

European Biopharmaceutical Review

ebr
Spring 2002
At the cutting edge of the latest industry developments, Samedan is adept at keeping the information you need at your fingertips. EBR provides a unique platform of communication for the market across Europe, North America and the rest of the developed world. To find out what's hot in the world of of biopharmaceuticals, take a look below at the range of articles featured in this issue of EBR.
   
Text
PDF
In her Editor's Letter, Dr Helen Abbott gives us a brief synopsis of the range and content of the articles in this issue of EBR  
view
bullet
STRATEGY AND FINANCE
In a period when most industries have experienced at least a 25 per cent downturn in M&A activity, Neal Ransome, Partner at PricewaterhouseCoopers Corporate Finance, reveals quite a different story for the pharmaceutical industry in A Record-Breaking US$27 Billion of Biotech Deals Supports Strong Pharma M&A Activity in 2001  
view
Geoff Newman, Managing Director of Interea International Ltd, explores the role of Interim Management Within Life Science Companies, and how it can make a real difference to the way companies perform  
view
Science and Innovation
In Pharmacogenetics and the Development of Anticancer Agents, Ann E. Ferentz, Senior Scientist and Manager of Scientific Communications at Variagenics, Inc, predicts a bright future as pharmacogenetics promises to improve patient quality of life and long-term prognosis  
view
Until recently there has been little progress in applying biotechnologically derived products in ophthalmic diseases. By asking Has Biotechnology Forgotten the Eye?, Dr Tom S Shepherd, President and Chief Executive Officer of Neurotech S.A., offers a forecast of how things look set to change  
view
Tina Kristensen, Research Scientist at NUNC A/S looks at how the increasing demand for more practical support for large-scale genome studies might be met in Polymer Substrate for DNA Microarrays  
view
bullet
Legal, Regulatory and Public Policy
At a time when an increasing number of concerned parents in the UK are rebelling against MMR as the only 'safe' vaccination alternative for their children, Dr Ian Gibson, Member of Parliament for Norwich North and Chair of the Commons Science and Technology Select Committee asks, Vaccination - Who Should We Trust?  
view
Alan Johnson, Minister of State for Employer Relations at the Department of Trade and Industry, considers the advantages of Striking a 'Work-Life Balance' in the Pharmaceutical Industry  
view
bullet
Preview
Preclinical and Clinical Evaluation of Therapeutic Vaccines - 21st-22nd January 2002, London  
view
2nd Annual BIA European CEO & Investor Conference - 27th-28th November 2001, London  
view
bullet
BIOINFORMATICS
Erich Bornberg-Bauer of UMBER Bioinformatics, School of Biological Sciences, and Mark Harvey and Andrew McMeekin of CRIC ESRC Centre for Research on Innovation and Competition, all at the University of Manchester, UK, pose the question Bioinformatics Education - Skills Shortage or Fundamental Shift in Skill Creation and Demand?  
view
In What Happens Next? Understanding the New FDA Guidelines for Digital ECG and Similar Data, Kevin J. Klingler, President of the Pharmaceutical Division of Biomedical Systems Corporation, answers some of the questions that arose after the November meeting  
view
Doru Felezeu, International Director at the Biolafitte & Moritz Division of Pierre Guerin, explains how bioinformatics are now implemented within fermentation in Intelligent Software Serving Control and Supervision of Fermentation Processes  
view
bullet
REGIONAL UPDATES
In, Michael Rappaport, Publications Supervisor at BIOTECanada, explains why Canada is the most cost-effective country in which to conduct biomedical R&D  
view
Dr Helen Abbott, Editor of EBR, takes a look at the factors that have been shaping the development of several thriving biotechnology clusters in Canada, in a Letter from Ontario  
view
As Quebec's significance in the Canadian economy is more certain than ever before, Perry Niro, Executive Director at BIOQuebec, highlights why Quebec Leads the Way in Canada's Biotechnology Sector  
view
In The Patenting of Biotechnology in Canada, Anita Nador, Partner in the Biotechnology and Pharmaceutical Practice Group at Bereskin & Parr, outlines Canada's approach to patenting requirements in the biotech sector  
view
bullet
INTERVIEW
EBR's Editor, Dr Helen Abbott, poses the question Xenova: Managing Consolidation and Change - A Source of Competitive Advantage for SMEs? In conversation with David Oxlade, Chief Executive Officer, and Dr John St Clair Roberts, Medical Director, of Xenova Group plc.  
view
bullet
INDUSTRY DYNAMICS
In Building Value Through Biotechnology Partnering, Mike Grey, Chief Business Officer at Structural GenomiX, Inc., analyses pharma-biotech and biotech-biotech collaborations, common reasons for failure and some models for success INTELLECTUAL PROPERTY AND TECH-TRANSFER  
view
bullet
INTELLECTUAL PROPERTY AND TECH-TRANSFER
Rainer Hilli, Partner, and Liisa Laurila, Lawyer, at Roschier Holmberg, Attorneys Ltd provide an update on the Donation of Organs and Tissues - New Legislation in Finland on the Prerequisites for Medical Research  
view
In the second part of a series of articles, Daniel Pavin, a Solicitor specialising in Intellectual Property and Information Technology Law with Taylor Joynson Garrett, looks at the role of warranties in Prevention and Cure - Intellectual Property Due Diligence and Warranties in Biotechnology and Pharmaceutical Technology Transfer Agreements  
view
Ben Rapinoja, Attorney at Borenius & Kemppinen Ltd, considers Certain Aspects Related to Shareholders' Agreements in Biotech Companies, and advises that a well-balanced agreement can create a solid ground for a biotechnology company's operations and business for many years ahead  
view
bullet
DEVELOPMENT AND PRODUCTION
Dr Lucy Dorrell, Clinician Scientist Fellow at the Medical Research Council's Human Immunology Unit, outlines the status of Therapeutic Vaccines for HIV-1 Infection - Past, Present and Future  
view
In A New Technology for Biopharmaceutical Analyses - Microfluidic-Based Lab-on-a-Chip, Tony Owen, Marketing Manager at Agilent Technologies, Germany, explains how the technology has rapidly established itself as a viable alternative to well-established techniques 94 Sophie Gaubert, Biology Manager, and Renй Laversanne, Site Director at Ethypharm S.A., consider the potential advances in protecting against local, respiratory or genital infections, or more generalised infectious diseases in Novel Multilamellar Vesicles for Mucosal and Systemic Antigen Delivery  
view
In Harnessing the Immune System Against Cancer, Dr Anthony Walker, CEO of Onyvax Ltd, assesses where we are now in the global quest for cancer immunotherapies  
view
Dr Ole Henrik Brekke, Director of New Technologies at Affitech AS, and Professor Inger Sandlie, Leader of the Antibody Engineering Group at the Department of Biology, University of Oslo, provide an overview of Activating T Cells With Trojan Horses - A Novel Approach to Vaccine Technology  
view
   
spacer
Edited by
Dr Deborah O'Neil,
Chief Executive and Scientific Officer,
NovaBiotics Ltd
Published quarterly in
January, April,
July and October

News and Press Releases

Bigneat is awarded the Queen’s Award by Lord-Lieutenant of Hampshire

Bigneat Ltd, winner of a Queen’s Award for Enterprise earlier this year, received their Award from Nigel Atkinson Esq, HM Lord-Lieutenant of Hampshire on 16th October at the Bigneat factory in Waterlooville.
More info >>

White Papers

The Key To Tableting Success: How To Choose The Right Tooling

Natoli Engineering Company, Inc.

Choosing the right tooling can increase tablet output, decrease waste and ultimately determine the success of a product launch.
More info >>

Industry Events

Outsourcing in clinical Trial Medical Devices Europe 2018

7-8 February 2018, Munich, Germany

Outsourcing in Clinical Trials: Medical Devices Europe has now reached its fifth birthday. This event is focused on Medical devices. At this event you will learn about the new regulations, which were released this may, regarding medical devices in more detail, from speakers who are the heads in their respective fields.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement